Screener
BridgeBio Pharma BBIO EBITDA
EBITDA at other companies
Other financials
Where this comes from
Calculated from BridgeBio Pharma’s reported figures.
The source filing: BridgeBio Pharma’s 10-Q, filed May 7, 2026. Open the filing →
- Filed
- May 7, 2026, 4:31 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001743881-26-000019
FAQ
- What is BridgeBio Pharma's EBITDA?
- BridgeBio Pharma (BBIO) reported EBITDA of -$104.77M in Q1 2026.
- How has BridgeBio Pharma's EBITDA changed year-over-year?
- BridgeBio Pharma's EBITDA decreased by 1.6% year-over-year, from -$103.09M to -$104.77M.
- What is the long-term trend for BridgeBio Pharma's EBITDA?
- Over 4 years (2021 to 2025), BridgeBio Pharma's EBITDA has grown at a -2.4% compound annual growth rate (CAGR), from -$570.79M to -$517.98M.
- What does EBITDA mean?
- Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.
Ask your AI about BridgeBio Pharma's ebitda.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude